3 Sources
[1]
AI accelerates discovery of neurodevelopmental disorder-associated genes
Researchers have developed an artificial intelligence (AI) approach that accelerates the identification of genes that contribute to neurodevelopmental conditions such as autism spectrum disorder, epilepsy and developmental delay. This new powerful computational tool can help fully characterize the genetic landscape of neurodevelopmental disorders, which is key to making accurate molecular diagnosis, elucidating disease mechanism and developing targeted therapies. The study appeared in the American Journal of Human Genetics. "Although researchers have made major strides identifying different genes associated with neurodevelopmental disorders, many patients with these conditions still do not receive a genetic diagnosis, indicating that there are many more genes waiting to be discovered," said first and co-corresponding author Dr. Ryan S. Dhindsa, assistant professor of pathology and immunology at Baylor College of Medicine and principal investigator at the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital. Typically, to discover new genes associated with a disease, researchers sequence the genomes of many individuals with the disorders and compare them to the genomes of people without the disorders. "We took a complementary approach," Dhindsa said. "We used AI to find patterns among genes already linked to neurodevelopmental diseases and predict additional genes that might also be involved in these disorders." The researchers looked for patterns in gene expression measured at the single-cell level from the developing human brain. "We found that AI models trained solely on these expression data can robustly predict genes implicated in autism spectrum disorder, developmental delay and epilepsy. But we wanted to take this work a step further," Dhindsa said. To enhance the models even further, the team incorporated more than 300 other biological features, including measures of how intolerant genes are to mutations, whether they interact with other known disease-associated genes and their functional roles in different biological pathways. "These models have exceptionally high predictive value," Dhindsa said. "Top-ranked genes were up to two-fold or six-fold, depending on the mode of inheritance, more enriched for high-confidence neurodevelopmental disorder risk genes compared to genic intolerance metrics alone. Additionally, some top-ranking genes were 45 to 500 times more likely to be supported by the literature than lower ranking genes." "We see these models as analytical tools that can validate genes that are beginning to emerge from sequencing studies but don't yet have enough statistical proof of being involved in neurodevelopmental conditions," Dhindsa said. "We hope that our models will accelerate gene discovery and patient diagnoses, and future studies will assess this possibility." Blake A. Weido, Justin S. Dhindsa, Arya J. Shetty, Chloe F. Sands, Slavé Petrovski, Dimitrios Vitsios and co-corresponding author Anthony W. Zoghbi contributed to this work. The authors are affiliated with one or more of the following institutions: Baylor College of Medicine, Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, AstraZeneca and the University of Melbourne. This work is supported by grants from NIH NINDS (F32 NS127854), NIH (DP5 OD036131), a Longevity Impetus Grant from Norn Group, Hevolution Foundation, Rosenkranz Foundation and grant K23MH121669.
[2]
AI accelerates discovery of neurodevelopmental disorder-associated genes
Researchers have developed an artificial intelligence (AI) approach that accelerates the identification of genes that contribute to neurodevelopmental conditions such as autism spectrum disorder, epilepsy and developmental delay. This new powerful computational tool can help fully characterize the genetic landscape of neurodevelopmental disorders, which is key to making accurate molecular diagnosis, elucidating disease mechanisms and developing targeted therapies. The study appears in The American Journal of Human Genetics. "Although researchers have made major strides in identifying different genes associated with neurodevelopmental disorders, many patients with these conditions still do not receive a genetic diagnosis, indicating that there are many more genes waiting to be discovered," said first and co-corresponding author Dr. Ryan S. Dhindsa, assistant professor of pathology and immunology at Baylor College of Medicine and principal investigator at the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital. Typically, to discover new genes associated with a disease, researchers sequence the genomes of many individuals with the disorders and compare them to the genomes of people without the disorders. "We took a complementary approach," Dhindsa said. "We used AI to find patterns among genes already linked to neurodevelopmental diseases and predict additional genes that might also be involved in these disorders." The researchers looked for patterns in gene expression measured at the single-cell level from the developing human brain. "We found that AI models trained solely on these expression data can robustly predict genes implicated in autism spectrum disorder, developmental delay and epilepsy. But we wanted to take this work a step further," Dhindsa said. To enhance the models even further, the team incorporated more than 300 other biological features, including measures of how intolerant genes are to mutations, whether they interact with other known disease-associated genes and their functional roles in different biological pathways. "These models have exceptionally high predictive value," Dhindsa said. "Top-ranked genes were up to two-fold or six-fold, depending on the mode of inheritance, more enriched for high-confidence neurodevelopmental disorder risk genes compared to genic intolerance metrics alone. Additionally, some top-ranking genes were 45 to 500 times more likely to be supported by the literature than lower-ranking genes." "We see these models as analytical tools that can validate genes that are beginning to emerge from sequencing studies but don't yet have enough statistical proof of being involved in neurodevelopmental conditions," Dhindsa said. "We hope that our models will accelerate gene discovery and patient diagnoses, and future studies will assess this possibility."
[3]
New AI tool enhances discovery of genes involved in neurodevelopmental conditions
Baylor College of MedicineFeb 26 2025 Researchers have developed an artificial intelligence (AI) approach that accelerates the identification of genes that contribute to neurodevelopmental conditions such as autism spectrum disorder, epilepsy and developmental delay. This new powerful computational tool can help fully characterize the genetic landscape of neurodevelopmental disorders, which is key to making accurate molecular diagnosis, elucidating disease mechanism and developing targeted therapies. The study appeared in the American Journal of Human Genetics. "Although researchers have made major strides identifying different genes associated with neurodevelopmental disorders, many patients with these conditions still do not receive a genetic diagnosis, indicating that there are many more genes waiting to be discovered," said first and co-corresponding author Dr. Ryan S. Dhindsa, assistant professor of pathology and immunology at Baylor College of Medicine and principal investigator at the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital. Typically, to discover new genes associated with a disease, researchers sequence the genomes of many individuals with the disorders and compare them to the genomes of people without the disorders. We took a complementary approach. We used AI to find patterns among genes already linked to neurodevelopmental diseases and predict additional genes that might also be involved in these disorders." Dr. Ryan S. Dhindsa, assistant professor of pathology and immunology, Baylor College of Medicine The researchers looked for patterns in gene expression measured at the single-cell level from the developing human brain. "We found that AI models trained solely on these expression data can robustly predict genes implicated in autism spectrum disorder, developmental delay and epilepsy. But we wanted to take this work a step further," Dhindsa said. To enhance the models even further, the team incorporated more than 300 other biological features, including measures of how intolerant genes are to mutations, whether they interact with other known disease-associated genes and their functional roles in different biological pathways. "These models have exceptionally high predictive value," Dhindsa said. "Top-ranked genes were up to two-fold or six-fold, depending on the mode of inheritance, more enriched for high-confidence neurodevelopmental disorder risk genes compared to genic intolerance metrics alone. Additionally, some top-ranking genes were 45 to 500 times more likely to be supported by the literature than lower ranking genes." "We see these models as analytical tools that can validate genes that are beginning to emerge from sequencing studies but don't yet have enough statistical proof of being involved in neurodevelopmental conditions," Dhindsa said. "We hope that our models will accelerate gene discovery and patient diagnoses, and future studies will assess this possibility." Blake A. Weido, Justin S. Dhindsa, Arya J. Shetty, Chloe F. Sands, Slavé Petrovski, Dimitrios Vitsios and co-corresponding author Anthony W. Zoghbi contributed to this work. The authors are affiliated with one or more of the following institutions: Baylor College of Medicine, Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital, AstraZeneca and the University of Melbourne. This work is supported by grants from NIH NINDS (F32 NS127854), NIH (DP5 OD036131), a Longevity Impetus Grant from Norn Group, Hevolution Foundation, Rosenkranz Foundation and grant K23MH121669. Baylor College of Medicine Journal reference: Dhindsa, R. S., et al. (2025) Genome-wide prediction of dominant and recessive neurodevelopmental disorder-associated genes. American Journal of Human Genetics. doi.org/10.1016/j.ajhg.2025.02.001.
Share
Copy Link
Researchers develop an AI-powered approach to identify genes associated with conditions like autism, epilepsy, and developmental delay, potentially revolutionizing genetic diagnosis and targeted therapies.
Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital have developed a groundbreaking artificial intelligence (AI) approach that accelerates the identification of genes associated with neurodevelopmental disorders such as autism spectrum disorder, epilepsy, and developmental delay 1. This innovative computational tool promises to revolutionize the field of genetic research and improve patient care.
Despite significant progress in identifying genes linked to neurodevelopmental disorders, many patients still do not receive a genetic diagnosis. Dr. Ryan S. Dhindsa, the study's first and co-corresponding author, explains, "Many patients with these conditions still do not receive a genetic diagnosis, indicating that there are many more genes waiting to be discovered" 2.
Traditional methods of gene discovery involve sequencing the genomes of individuals with and without the disorders and comparing them. However, the research team took a different approach:
To further improve the model's predictive power, the team incorporated over 300 additional biological features, including:
The enhanced AI models demonstrated exceptional predictive value:
Dr. Dhindsa envisions these AI models as powerful analytical tools that can:
The study, published in the American Journal of Human Genetics, was a collaborative effort involving researchers from Baylor College of Medicine, Texas Children's Hospital, AstraZeneca, and the University of Melbourne. The research was supported by grants from various organizations, including the NIH, Norn Group, Hevolution Foundation, and Rosenkranz Foundation 3.
As this AI-powered approach continues to develop, it holds the promise of transforming our understanding of neurodevelopmental disorders and improving outcomes for patients worldwide.
Summarized by
Navi
[2]
NVIDIA CEO Jensen Huang confirms the development of the company's most advanced AI architecture, 'Rubin', with six new chips currently in trial production at TSMC.
2 Sources
Technology
17 hrs ago
2 Sources
Technology
17 hrs ago
Databricks, a leading data and AI company, is set to acquire machine learning startup Tecton to bolster its AI agent offerings. This strategic move aims to improve real-time data processing and expand Databricks' suite of AI tools for enterprise customers.
3 Sources
Technology
17 hrs ago
3 Sources
Technology
17 hrs ago
Google is providing free users of its Gemini app temporary access to the Veo 3 AI video generation tool, typically reserved for paying subscribers, for a limited time this weekend.
3 Sources
Technology
9 hrs ago
3 Sources
Technology
9 hrs ago
Broadcom's stock rises as the company capitalizes on the AI boom, driven by massive investments from tech giants in data infrastructure. The chipmaker faces both opportunities and challenges in this rapidly evolving landscape.
2 Sources
Technology
17 hrs ago
2 Sources
Technology
17 hrs ago
Apple is set to introduce new enterprise-focused AI tools, including ChatGPT configuration options and potential support for other AI providers, as part of its upcoming software updates.
2 Sources
Technology
17 hrs ago
2 Sources
Technology
17 hrs ago